Depression in association with neutrophil-to-lymphocyte, platelet-to-lymphocyte, and advanced lung cancer inflammation index biomarkers predicting lung cancer survival DOI Creative Commons
Barbara L. Andersen, John Myers, Tessa R. Blevins

et al.

PLoS ONE, Journal Year: 2023, Volume and Issue: 18(2), P. e0282206 - e0282206

Published: Feb. 24, 2023

Lung cancer is a product of inflammation and dysfunctional immune system, depression has similar dysregulation. Depression disproportionately affects lung patients, having the highest rates all cancers. Systemic are both predictive non-small cell (NSCLC) survival, but existence extent any co-occurrence unknown. Studied association between systemic ratio (SIR) biomarker levels patients’ depressive symptoms, with hypothesis that severity would be significantly associated prognostically poor inflammation. Newly diagnosed stage-IV (NSCLC; N = 186) patients were enrolled (ClinicalTrials.gov Identifier: NCT03199651) blood draws self-reports (Patient Health Questionnaire-9) obtained. For SIRs, counts neutrophils (N), lymphocytes (L), platelets (P) abstracted for (R) calculations NLR, PLR, Advanced Inflammation Index (ALI). Patients followed biomarkers tested as predictors 2-year overall survival (OS) to confirm their relevance. Next, multivariate linear regressions associations ALI. Overall mortality was 61% (113/186). Cox model analyses confirmed higher NLR [hazard (HR) 1.91; p 0.001] PLR (HR 2.08; p<0.001), along lower ALI 0.53; 0.005), worse OS. Adjusting covariates, reliably (p ≤ 0.02). moderate/severe symptoms 2 3 times more likely have levels. Novel data show lung-relevant biomarkers, assessed at diagnosis/pretreatment. The same SIRs found prognostic Intensive study depression, combined measures biology needed extend these findings discover mechanisms toxicity NSCLC treatment responses survival.

Language: Английский

Recent advances in non-small cell lung cancer targeted therapy; an update review DOI Creative Commons
Mahmood Araghi, Reza Mannani,

Ali Heidarnejad maleki

et al.

Cancer Cell International, Journal Year: 2023, Volume and Issue: 23(1)

Published: Aug. 11, 2023

Abstract Lung cancer continues to be the leading cause of cancer-related death worldwide. In last decade, significant advancements in diagnosis and treatment lung cancer, particularly NSCLC, have been achieved with help molecular translational research. Among hopeful breakthroughs therapeutic approaches, advances targeted therapy brought most successful outcomes NSCLC treatment. therapy, antagonists target specific genes, proteins, or microenvironment tumors supporting growth survival. Indeed, can managed by blocking genes related tumor cell progression without causing noticeable damage normal cells. Currently, efforts focused on improving aspects regarding encouraging quality life patients. Treatment for is changing rapidly due pace scientific Accordingly, this updated study aimed discuss antigens comprehensively therapy-related agents NSCLC. The current also summarized available clinical trial studies

Language: Английский

Citations

143
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01 DOI Creative Commons
Toshio Shimizu, Jacob Sands, Kiyotaka Yoh

et al.

Journal of Clinical Oncology, Journal Year: 2023, Volume and Issue: 41(29), P. 4678 - 4687

Published: June 16, 2023

This first-in-human, dose-escalation and dose-expansion study evaluated the safety, tolerability, antitumor activity of datopotamab deruxtecan (Dato-DXd), a novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate in solid tumors, including advanced non-small-cell lung cancer (NSCLC).

Language: Английский

Citations

69
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study DOI
Luis Paz‐Ares, Óscar Juan, Giannis Mountzios

et al.

Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 42(24), P. 2860 - 2872

Published: May 31, 2024

The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti-PD-(L)1, and targeted treatment for actionable genomic alterations (AGAs). Primary analysis is reported.

Language: Английский

Citations

28
Advancing Optical Nanosensors with Artificial Intelligence: A Powerful Tool to Identify Disease-Specific Biomarkers in Multi-omics Profiling DOI
Bakr Ahmed Taha,

Zahraa Mustafa Abdulrahm,

Ali J. Addie

et al.

Talanta, Journal Year: 2025, Volume and Issue: 287, P. 127693 - 127693

Published: Feb. 4, 2025

Language: Английский

Citations

4
The state of the art for artificial intelligence in lung digital pathology DOI

Vidya Sankar Viswanathan,

Paula Toro, Germán Corredor

et al.

The Journal of Pathology, Journal Year: 2022, Volume and Issue: 257(4), P. 413 - 429

Published: May 17, 2022

Abstract Lung diseases carry a significant burden of morbidity and mortality worldwide. The advent digital pathology (DP) an increase in computational power have led to the development artificial intelligence (AI)‐based tools that can assist pathologists pulmonologists improving clinical workflow patient management. While previous works explored advances approaches for breast, prostate, head neck cancers, there has been growing interest applying these technologies lung as well. application AI on radiology images better characterization indeterminate nodules, fibrotic disease, cancer risk stratification well documented. In this article, we discuss methodologies used build DP, describing various hand‐crafted deep learning‐based unsupervised feature approaches. Next, review across wide spectrum including cancer, tuberculosis, idiopathic pulmonary fibrosis, COVID‐19. We utility novel imaging biomarkers different types problems quantification like PD‐L1, disease diagnosis, stratification, prediction response treatments such immune checkpoint inhibitors. also look briefly at some emerging applications DP multimodal data analysis, 3D pathology, transplant rejection. Lastly, future DP‐based tools, challenges with regulatory approval, developing reimbursement models, planning deployment, addressing biases. © 2022 Authors. Journal Pathology published by John Wiley & Sons Ltd behalf Pathological Society Great Britain Ireland.

Language: Английский

Citations

65
The 2021 Global Lung Cancer Therapy Landscape DOI Creative Commons
Dhruba Deb,

Amy Moore,

Upal Roy

et al.

Journal of Thoracic Oncology, Journal Year: 2022, Volume and Issue: 17(7), P. 931 - 936

Published: April 27, 2022

The lung cancer treatment landscape has substantially evolved over the past decade. However, a systematic analysis of current global drug development not been conducted.We curated and analyzed comprehensive list therapeutic entities (TEs) in preclinical clinical trials for cancer.On basis our 707 TEs, we found consistent forward trajectory pipeline both NSCLC SCLC. Most TEs were advanced stages trials. Targeted therapies continue to dominate non-immuno-oncology space. Immuno-oncology targets are expanding beyond inhibitors programmed death-ligand 1 axis.Our highlights robust portfolio suggests that is going become even more biomarker-driven.

Language: Английский

Citations

40
Clinical applications of mass spectrometry‐based proteomics in cancer: Where are we? DOI Creative Commons
Emma L. Boys, Jia Liu, Phillip J. Robinson

et al.

PROTEOMICS, Journal Year: 2022, Volume and Issue: 23(7-8)

Published: Aug. 15, 2022

Tumor tissue processing methodologies in combination with data-independent acquisition mass spectrometry (DIA-MS) have emerged that can comprehensively analyze the proteome of multiple tumor samples accurately and reproducibly. Increasing recognition adoption these technologies has resulted a tranche studies providing novel insights into cancer classification systems, functional biology, biomarkers, treatment response drug targets. Despite this, some limited exceptions, MS-based proteomics not yet been implemented routine clinical practice. Here, we summarize use DIA-MS may pave way for future applications, highlight role alternative MS multi-omic strategies. We discuss limitations challenges this field to date propose steps integrating proteomic data clinic.

Language: Английский

Citations

40
Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer DOI Open Access
Shenduo Li,

Guilherme Sacchi de Camargo Correia,

Jing Wang

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(11), P. 2899 - 2899

Published: May 24, 2023

Lung cancer remains the leading cause of cancer-related mortality worldwide. Non-small-cell lung (NSCLC) is most common type and still incurable for patients at advanced stage. Targeted therapy an effective treatment that has significantly improved survival in NSCLC with actionable mutations. However, resistance occurs widely among to disease progression. In addition, many oncogenic driver mutations lack targeted agents. New drugs are being developed tested clinical trials overcome these challenges. This review aims summarize emerging have been conducted or initiated through first-in-human past year.

Language: Английский

Citations

40
Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non–Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers DOI Creative Commons
Edurne Arriola, Reyes Bernabé,

Rosario García Campelo

et al.

JCO Precision Oncology, Journal Year: 2023, Volume and Issue: 7

Published: March 1, 2023

PURPOSE The aim of this study was to assess the cost-effectiveness using next-generation sequencing (NGS) versus single-gene testing (SgT) for detection genetic molecular subtypes and oncogenic markers in patients with advanced non–small-cell lung cancer (NSCLC) setting Spanish reference centers. METHODS A joint model combining decision tree partitioned survival models developed. two-round consensus panel performed describe clinical practice centers, providing data on rate, prevalence alterations, turnaround times, treatment pathways. Treatment efficacy utility values were obtained from literature. Only direct costs (euros, 2022), databases, included. lifetime horizon considered, so a 3% discount rate future outcomes considered. Both deterministic probabilistic sensitivity analyses uncertainty. RESULTS target population 9,734 NSCLC estimated. If NGS used instead SgT, 1,873 more alterations would be detected 82 could potentially enrolled trials. In long term, provide 1,188 additional quality-adjusted life-years (QALYs) compared SgT. On other hand, incremental cost SgT €21,048,580 euros (€1,333,288 diagnosis phase only). cost-utility ratios €25,895 per QALY gained, below standard thresholds. CONCLUSION Using centers metastatic cost-effective strategy over

Language: Английский

Citations

37
Nanomedicine Combats Drug Resistance in Lung Cancer DOI
Xiuli Zheng, Xiao-Hai Song,

Guonian Zhu

et al.

Advanced Materials, Journal Year: 2023, Volume and Issue: 36(3)

Published: Nov. 16, 2023

Lung cancer is the second most prevalent and leading cause of cancer-related death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, radiotherapy are currently available as treatment methods. However, drug resistance a significant factor in failure lung treatments. Novel therapeutics have been exploited to address complicated mechanisms advancement nanomedicine extremely promising terms overcoming resistance. Nanomedicine equipped with multifunctional tunable physiochemical properties alignment tumor genetic profiles can achieve precise, safe, effective while minimizing or eradicating cancer. Here, this work reviews discovered for radiotherapy, outlines novel strategies development against This focuses on engineering design, customized delivery, current challenges, clinical translation application resistant

Language: Английский

Citations

36